Jade Biosciences, Inc. - Common Stock (JBIO)

Jade Biosciences (NASDAQ:JBIO) said interim results from a Phase 1 healthy volunteer study of JADE101 showed rapid and durable reductions in serum IgA, supporting the company’s plan to advance the antibody into patient studies for IgA nephropathy. Chief Executive Officer Tom Frohlich said JADE101,

This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials.

This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.

This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications.